Fozia Ahmed
A5075620293- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiac Structural Anomalies and Repair
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Diabetes Treatment and Management
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Hormonal Regulation and Hypertension
- Cardiovascular and exercise physiology
- COVID-19 and healthcare impacts
- Mechanical Circulatory Support Devices
- Pericarditis and Cardiac Tamponade
- Advanced X-ray and CT Imaging
- Atrial Fibrillation Management and Outcomes
- Body Contouring and Surgery
- Coronary Interventions and Diagnostics
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Viral Infections and Immunology Research
- Acute Myocardial Infarction Research
- GDF15 and Related Biomarkers
Manchester University NHS Foundation Trust
2016-2025
Keele University
2021-2025
Manchester University
1984-2025
Dubai Medical College
2024
Manchester Academic Health Science Centre
2017-2024
University of Missouri–Kansas City
2023-2024
University of Manchester
2013-2024
Health Sciences Centre
2024
Basildon Hospital
2024
Manchester Royal Infirmary
2013-2023
BackgroundHeart failure with preserved ejection fraction is increasing in prevalence and associated a high symptom burden functional impairment, especially persons obesity. No therapies have been approved to target obesity-related heart fraction.MethodsWe randomly assigned 529 patients who had body-mass index (the weight kilograms divided by the square of height meters) 30 or higher receive once-weekly semaglutide (2.4 mg) placebo for 52 weeks. The dual primary end points were change from...
Obesity and type 2 diabetes are prevalent in patients with heart failure preserved ejection fraction characterized by a high symptom burden. No approved therapies specifically target obesity-related persons diabetes.
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function reduced body weight in patients with obesity phenotype of heart failure preserved ejection fraction (HFpEF). This prespecified analysis examined effects on dual primary endpoints (change Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) weight) confirmatory secondary 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change KCCQ-CSS 6MWD)...
Obesity is associated with adverse cardiac remodeling and a key driver for the development progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to improve HF-related symptoms physical limitations, body weight, exercise function in patients obesity-related preserved ejection fraction (HFpEF), but effects on structure this population remain unknown.
Abstract Background and Aims What is the relationship between blood tests for iron deficiency, including anaemia, response to intravenous in patients with heart failure? Methods In IRONMAN trial, 1137 failure, ejection fraction ≤ 45%, either serum ferritin < 100 µg/L or transferrin saturation (TSAT) 20% were randomized ferric derisomaltose (FDI) usual care. Relationships investigated baseline anaemia severity, TSAT, changes haemoglobin from 4 months, Minnesota Living Heart Failure...
Abstract Aims To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk developing heart failure. Methods results Randomized, open-label, blinded-endpoint trial comparing (50 mg/day) or control for up to 9 months with, high of, coronary disease raised plasma B-type natriuretic peptides. The primary endpoint was interaction between baseline serum galectin-3 changes procollagen type-III N-terminal pro-peptide (PIIINP) participants assigned...
Abstract Aims We hypothesized that a decline in admissions with heart failure during COVID-19 pandemic would lead to reciprocal rise mortality for patients the community. Methods and results used National Heart Failure Audit data identify 36 974 adults who had hospital admission primary diagnosis of between February May either 2018, 2019, or 2020. Hospital 2018/19 averaged 160/day but were much lower 2020, reaching nadir 64/day on 27 March 2020 [incidence rate ratio (IRR): 0.40, 95%...
Importance In the Revascularization for Ischemic Ventricular Dysfunction (REVIVED-BCIS2) trial, percutaneous coronary intervention (PCI) did not improve outcomes patients with ischemic left ventricular dysfunction. Whether myocardial viability testing had prognostic utility these or identified a subpopulation who may benefit from PCI remained unclear. Objective To determine effect of extent viable and nonviable myocardium on effectiveness PCI, prognosis, improvement in function. Design,...
Complete revascularization of coronary disease has been linked to improved outcomes in patients with preserved left ventricular (LV) function. To identify the impact complete severe LV dysfunction. Patients enrolled REVIVED-BCIS2 trial were eligible if baseline/procedural angiograms and viability studies available for analysis by independent core laboratories. Anatomical viability-guided completeness measured myocardial indices (RIcoro RImyo) respectively, where RIcoro=[change BCIS Jeopardy...
Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients heart failure reduced ejection fraction (HFrEF) and deficiency. However, its effects across different age groups remain unclear. This analysis of the Effectiveness Iron Treatment versus Standard Care Patients Heart Failure Deficiency (IRONMAN) trial explored efficacy safety FDI groups. Methods The IRONMAN was a prospective, open-label, blinded end point randomised controlled...
AimsTo examine the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early diagnosis cardiac implantable electronic device (CIED) generator pocket infection.
The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy safety of anti-fibrotic pirfenidone chronic failure ejection fraction (HFpEF) myocardial fibrosis. HFpEF a diverse syndrome associated substantial morbidity mortality. Myocardial fibrosis key pathophysiological mechanism fibrotic burden strongly independently adverse outcome. Pirfenidone an oral agent, without haemodynamic effect, that leads...
Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization coronary artery bypass graft or percutaneous intervention often recommended for these before implantation a cardiac defibrillator because it assumed that this may reduce the incidence fatal and potentially arrhythmias, although premise has not been evaluated randomized trial to date.
Abstract Aims Clinical pathways have been shown to improve outcomes in patients with heart failure (HF). Although HF often a cardiac implantable electronic device, few studies reported the utility of device‐derived risk scores augment and organize care. TriageHF Plus is device‐based clinical pathway (DHFP) that uses remote monitoring alerts trigger structured telephone assessment for stability optimization. We aimed evaluate impact on hospitalizations describe associated workforce burden....
Abstract Aims Remote monitoring of patients with physiological data derived from cardiac implanted electronic devices (CIEDs) offers potential to reconfigure clinical services. The ‘Heart Failure Risk Score' (HFRS) uses input integrated device risk‐stratify as low‐risk, medium‐risk, or high‐risk a heart failure event in the next 30 days. This study aimed evaluate novel pathway utilizing combination CIED risk‐stratification and telephone triage identify worsening (WHF). Methods results A...
Abstract Aims The coronavirus disease 2019 (COVID‐19) pandemic has created significant challenges to healthcare globally, necessitating rapid restructuring of service provision. This questionnaire survey was conducted amongst adult heart failure (HF) patients in the United Kingdom (UK), understand impact COVID‐19 upon HF services. Methods and results by Pumping Marvellous Foundation, a UK patient charity. ‘Survey Monkey’ used disseminate Foundation 's online group 10 hospitals (outpatient...